|View printer-friendly version|
New Patents Supplement Existing Portfolio of More Than 700 Patents and Patent Applications Owned or Licensed by BioTime Family of Companies Worldwide
“Patents are a key asset for biotechnology companies, especially in
cases of emerging platform technologies such as pluripotent stem
cell-based regenerative medicine,” said
Select examples of new patents issued in
United Statespatent 9074181 – Claims methods for the culture of undifferentiated stem cells while in suspension as opposed to attached to the surface of a vessel. Such suspension culture enables full use of the three-dimensional space of the culture vessel and provides a rapid, efficient way of expanding undifferentiated stem cells, which may substantially reduce the cost of producing such cells in commercial quantities.
United Statespatent 9085756 – Claims methods of screening for factors that differentiate primate pluripotent stem cells into pancreatic islet cells. These methods are useful for the manufacture of pancreatic islet cells for drug discovery and transplantation in humans for the treatment of diabetes.
United Statespatents 9404085 and 9115343 – Claim culture media for differentiating stem cells to cardiac muscle cells, and methods for screening factors that induce differentiation of stem cells to cardiac muscle cells, respectively. The patents may have future uses in the manufacture of cardiac muscle cells from pluripotent stem cells.
United Statespatent 9175263 – Claims peptide compositions that bind to and target a wide array of human progenitor cell lines. This patent is useful in the identification, screening, and purification of various cell lines, and potentially other diverse uses in preparing certain human cell types for use in research and therapy.
United Statespatents 9243229 and 9238794 – Claim cultures of cardiac muscle cells and oligodendrocyte progenitor cells on cell culture surfaces containing certain specific polymers, respectively. These patents allow culturing of the claimed cell types in an environment free of animal-derived components and are therefore potentially useful for future therapeutic applications such as transplantation or drug testing.
Additional patents issued in the same time period include:
United Statespatents 9074182, and 9115360
Australiapatents 2009209157, 2009209167, 2012203350, 2009228215, 2011218041 and 2012225784
Canadapatents 2692325, 2350210, 2453438, 2573437, 2569485, 2549295 and 2489712
Chinapatents ZL200910152133.X, ZL201010528128.7 and 201080041322.0
Japanpatents 5770213, 5792428, 5917429 and 5926240
In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for
To receive ongoing
Dan L. Lawrence, 510-775-0510
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Gotham Communications, LLC
Bill Douglass, 646-504-0890